Generic Name:
immune globulin human and recombinant human hyaluronidase
Project Status:
Active
Therapeutic Area:
Humoral immunodeficiency
Manufacturer:
Takeda Canada Inc.
Brand Name:
HyQvia
Project Line:
Reimbursement Review
Project Number:
ST0695-000
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
As replacement therapy for primaryhumoral immunodeficiency (PI) and secondary humoralimmunodeficiency (SI) in adult patients.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
N/A
Indications:
As replacement therapy for primaryhumoral immunodeficiency (PI) and secondary humoralimmunodeficiency (SI) in adult patients.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.